{
    "2018-04-06": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Noteworthy ETF Inflows: VTV, USB, LLY, MS",
                "features": {
                    "keywords": [
                        "ETF",
                        "Inflows",
                        "VTV",
                        "USB",
                        "LLY",
                        "MS"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "Pharma Stock Roundup: LLY's Cyramza Shines in Cancer Study, PFE & AZN in Focus",
                "features": {
                    "keywords": [
                        "Pharma",
                        "Stock",
                        "LLY",
                        "Cyramza",
                        "Cancer",
                        "Study",
                        "PFE",
                        "AZN"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-12",
                "original_text": "Pharma Stock Roundup: LLY's Cyramza Shines in Cancer Study, PFE & AZN in Focus",
                "features": {
                    "keywords": [
                        "Pharma",
                        "Stock",
                        "LLY",
                        "Cyramza",
                        "Cancer",
                        "Study",
                        "PFE",
                        "AZN"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-01",
                "original_text": "Wired News â€“ Eli Lilly's Phase-3 REACH-2 Study of CYRAMZA(R) Met its Primary Endpoint of Overall Survival",
                "features": {
                    "keywords": [
                        "Wired",
                        "News",
                        "Eli",
                        "Lilly",
                        "Phase-3",
                        "REACH-2",
                        "Study",
                        "CYRAMZA(R)",
                        "Primary",
                        "Endpoint",
                        "Overall",
                        "Survival"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}